In hematologic malignancies [42] cervical cancer [43] and multiple myeloma [45] SOX6 demonstrates tumor-suppressive properties by inhibiting proliferation, inducing cellular senescence or apoptosis, and regulating critical pathways including TGFβ2-Smad2/3 and LIN28B-MYC [43, 44]. Here, MYC is linked to plasma cell myeloma.